Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Join former FDA Investigations Branch Director Ricki Chase – now with Lachman Consultants – as she draws on her 16 years of agency experience to bring you the latest insights into FDA inspections, interactions and expectations.
Compliance 360 Podcast Survival Guide is brought to you by Medtech Insight
With Medtech Insight, you can access extensive coverage of global medtech news and insight. Grasp global trends and source information on the impact of technologies like diagnostic imaging, drug delivery, 3-D printing and more.
Podcast Lineup
February 6
Handling Difficult US FDA Investigators
February 13
Getting The Most Out Of Your Inspection:
Close-Out Meetings
February 20
Building Trust With US FDA:
Can It Be Done?
February 27
How To Better Manage Your Quality Data
March 6
Medical Device 483s:
US FDA’s Top 5 Observations
March 13
Don’t Do That!
How To Respond To FDA-483s
March 20
Factors Feeding Your Inspection Cycle:
A New Paradigm
March 27
Patient Influence On US FDA’s
Enforcement Strategy
As a subscriber, you’ll enjoy anytime, any-device access to the industry’s key thinkers and opinion leaders. Plus, you can connect with the commercial market developments and information you need for success.
Medtech Insight subscribers – simply log in to your account to listen to the podcast each week.
Not a subscriber? Get a free trial below.
In Vivo: strategic insights for life sciences decision-maker...
Pharma Intelligence offers a wealth of pharmaceutical industry news and strategic insight into the healthcare & biotechnology markets from around the world. Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.
Scrip: industry news and insights
The Swiss major's pharma chief tells Scrip that its gene therapy for SMA offers much more than Biogen's Spinraza for both patients and payers, noting that the company is ready with alternative payment models for the pricey treatment as soon as approvals for Zolgensma are granted.
Topics Business strategies Drug approval Drug development landscape Drug review
Scrip: industry news and insights
By Emily Hayes
In second Phase III diabetes study to report, oral GLP-1 agonist semaglutide misses some weight loss goals when compared with Boehringer/Lilly's SGLT-2 inhibitor Jardiance.
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Get a window into what the leading players across the biopharma, medtech, and diagnostics industries are thinking, as well as important insight into what your competitors are doing. Build your strategy with In Vivo.
In the continually evolving medtech competitive landscape, it is vital to stay up-to-date with key events. With Meddevicetracker, you’ll be able to anticipate upcoming filings, research clinical trial dates and data, and access market size information and expert forecasts, all in one place.
Looking for more products Product Finder
